Is major depressive disorder a metabolic encephalopathy?
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Metabolic encephalopathy is an acute disturbance in cellular metabolism in the brain evoked by conditions of hypoxia, hypoglycaemia, oxidative stress and/or inflammation. It usually develops acutely or subacutely and is reversible if the systemic disorder is treated. If left untreated, however, metabolic encephalopathy may result in secondary structural damage to the brain. Most encephalopathies are present with neuropsychiatric symptoms, one in particular being depression. However, mood disorders are often co‐morbid with cardiovascular, liver, kidney and endocrine disorders, while increasing evidence concurs that depression involves inflammatory and neurodegenerative processes. This would suggest that metabolic disturbances resembling encephalopathy may underscore the basic neuropathology of depression at a far deeper level than currently realized. Viewing depression as a form of encephalopathy, and exploiting knowledge gleaned from our understanding of the neurochemistry and treatment of metabolic encephalopathy, may assist in our understanding of the neurobiology of depression, but also in realizing new ideas in the pharmacotherapy of mood disorders. Copyright © 2008 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rozanski, A., Blumenthal, J. A., & Kaplan, J. (1999) · Circulation · doi:10.1161/01.cir.99.16.2192 · Cited by 2,846
Glucocorticoids and Hippocampal Atrophy in Neuropsychiatric Disorders
Sapolsky, R. M. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.10.925 · Cited by 2,016
New approaches to antidepressant drug discovery: beyond monoamines
Berton, O., & Nestler, E. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1846 · Cited by 1,589 · cited 2×
“Despite this knowledge, current drug treatment of depression remains steadfastly resigned to addressing the disorder at the synaptic level, and as such simply acting to switch on the cascade from outside the cell (Manji et al., 2001; Berton and Nestler, 2006).”
BackgroundInfluentialThe cellular neurobiology of depression
Manji, H. K., Drevets, W. C., & Charney, D. S. (2001) · Nature Medicine · doi:10.1038/87865 · Cited by 1,182 · cited 4×
“cyclic AMP response element binding protein (CREB), NO, B-cell lymphoma 2 (bcl-2), glycogen synthase kinase (GSK) and extracellular signalregulated kinase (ERK) leading to gene transcription and protein synthesis (Manji et al., 2001; D’Sa and Duman, 2002; Berton and Nestler, 2006).”
BackgroundInfluentialStarkman, M. N., Gebarski, S. S., Berent, S., & Schteingart, D. E. (1992) · Biological Psychiatry · doi:10.1016/0006-3223(92)90079-f · Cited by 840 · cited 1×
“Indeed, Cushing’s disease is associated with reduced hippocampal volume as well as prominent cognitive decrements and depression (Starkman et al., 1992; Starkman et al., 2001).”
BackgroundMüller, N., Schwarz, M. J., Dehning, S., Douhe, A., Cerovecki, A., Goldstein-Müller, B., Spellmann, I., Hetzel, G., Maino, K., Kleindienst, N., et al. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001805 · Cited by 794
Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments
Krystal, J. H., Sanacora, G., Blumberg, H., Anand, A., Charney, D. S., Marek, G., Epperson, C. N., Goddard, A., & Mason, G. F. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001021 · Cited by 553
Kendler, K. S., Thornton, L. M., & Gardner, C. O. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.4.582 · Cited by 480
Homocysteine and folate metabolism in depression
Bottiglieri, T. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.06.021 · Cited by 459
Decrease in cortisol reverses human hippocampal atrophy following treatment of Cushing’s disease
Starkman, M. N., Giordani, B., Gebarski, S. S., Berent, S., Schork, M. A., & Schteingart, D. E. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00203-6 · Cited by 455 · cited 1×
“Recent evidence now suggests that stress/cortisol-induced neuronal remodelling, as well as damage are expedited by exposure to elevated levels of glucocorticoids (Starkman et al., 1999).”
BackgroundGlutamate and Depression: Clinical and Preclinical Studies
PAUL, I. A., & SKOLNICK, P. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.016 · Cited by 408 · cited 2×
“…and Skolnick, 2003), has in recent years become increasingly recognized as being involved in the neuropathology and treatment of affective illnesses, particularly in mediating rapid neuronal regulation throughout the CNS of especially monoaminergic pathways (Harvey, 1996; Paul and Skolnick, 2003).”
BackgroundSerotonin-1A receptor imaging in recurrent depression: replication and literature review
Drevets, W. C., Thase, M. E., Moses-Kolko, E. L., Price, J., Frank, E., Kupfer, D. J., & Mathis, C. (2007) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2007.06.008 · Cited by 399 · cited 1×
“Major depressive disorder is associated with a widespread reduction in 5-HT1A receptor binding (Sargent et al., 2000; Drevets et al., 2007), as well as elevated 5HT2A receptor density (Leonard, 2003).”
BackgroundA double-blind, placebo-controlled study of antidepressant augementation with mirtazapine
Carpenter, L. L., Yasmin, S., & Price, L. H. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01262-8 · Cited by 244
Cannon, D. M., Ichise, M., Rollis, D., Klaver, J. M., Gandhi, S. K., Charney, D. S., Manji, H. K., & Drevets, W. C. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.016 · Cited by 219
Altamura, C., Maes, M., Dai, J., & Meltzer, H. Y. (1995) · European Neuropsychopharmacology · doi:10.1016/0924-977x(95)00033-l · Cited by 193
Barbosa, L., Berk, M., & Vorster, M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0407 · Cited by 165
Leinonen, E., Skarstein, J., Behnke, K., ??gren, H., & Th Helsdingen, J. (1999) · International Clinical Psychopharmacology · doi:10.1097/00004850-199911000-00002 · Cited by 146
Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis
Kasper, S., Spadone, C., Verpillat, P., & Angst, J. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000194375.42589.c3 · Cited by 100
Controlled trial of d-cycloserine adjuvant therapy for treatment-resistant major depressive disorder
Heresco-Levy, U., Javitt, D. C., Gelfin, Y., Gorelik, E., Bar, M., Blanaru, M., & Kremer, I. (2006) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.03.004 · Cited by 89 · cited 1×
“Interestingly, positive modulators of the NMDA receptor have also been found to be of value in treatment resistance depression (Heresco-Levy et al., 2006), again emphasizing the bi-directional role of glutamate in mood, and which is evident in HE.”
BackgroundTwo-week delay in onset of action of antidepressants: new evidence
Mitchell, A. J. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.bp.105.011692 · Cited by 82
Cited by
Bipolar and major depressive disorder: Neuroimaging the developmental-degenerative divide
Savitz, J., & Drevets, W. C. (2009) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.01.004 · Cited by 494
Peripheral Markers of Depression
Nobis, A., Zalewski, D., & Waszkiewicz, N. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123793 · Cited by 197
Brand, S., Moller, M., & Harvey, B. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150307004545 · Cited by 95
Self-citation
Metadata
- Authors
- Harvey, B. H.
- Venue
- Human Psychopharmacology: Clinical and Experimental
- Publisher
- Wiley
- Published
- 2008-04-25
- Volume
- 23
- Issue
- 5
- Pages
- 371-384
- ISSN
- 0885-6222 (ISSN-L)
- 1099-1077
- OpenAlex
- W1999214302
- Cited by
- 36
- References
- 20
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.